Short- and long-term reproducibility of capsaicin cough challenge testing
Short- and long-term reproducibility of capsaicin cough challenge testing
复制标题
DOI：
10.1016/s1094-5539(02)00149-9
复制
发表时间：
2003-01-01
影响因子：
3.2
通讯作者：
Dicpinigaitis, PV
中科院分区：
文献类型：
--
作者：
Dicpinigaitis, PV
止咳剂辣椒素已在临床研究中获得普遍使用，因为它以安全，剂量依赖性和可重复的方式诱导咳嗽。然而，辣椒素激发试验的重现性仅在短期内得到证实（研究间隔为20分钟至14天）。在本研究中，对作者实验室进行的数百次咳嗽激发的数据进行评价，得到两组40例受试者。在短期再现性组中，受试者每隔14天进行咳嗽激发。长期重现性组的受试者至少间隔6个月（平均16.7 +/- 2.4个月，范围6-62个月）接受挑战。所有受试者都是健康的成年志愿者，他们经历了相同的咳嗽激发试验，该试验包括吸入递增的加倍浓度（μ M）的辣椒素，直到达到诱导两次或更多次（C-2）和五次或更多次咳嗽（C-5）的浓度。根据重复研究产生的C-2和C-5值在初始值的1倍和2倍浓度范围内的受试者百分比评价结果。总体而言，重现性相当好，90-100%的挑战产生的C-2和C-5值在两个倍增浓度内。C-5的短期重现性上级C-2，表明C-5是涉及在14天内进行的连续咳嗽激发试验的首选终点。(C)2003爱思唯尔科技有限公司版权所有。
The tussive agent capsaicin has achieved common usage in clinical research because it induces cough in a safe, dose-dependent, and reproducible manner. However, the reproducibility of capsaicin challenge testing has been demonstrated only in the short term (study intervals of 20 min to 14 days). In the present study, evaluation of data from several hundred cough challenges performed in the author's laboratory yielded two groups of 40 subjects. In the short-term reproducibility group, subjects underwent cough challenge at an interval of 14 days. Subjects in the long-term reproducibility group were challenged at intervals of at least 6 months (mean 16.7 +/- 2.4 months, range 6-62 months). All subjects were healthy adult volunteers who underwent identical cough challenge testing, which involved inhalation of incremental, doubling concentrations (muM) of capsaicin until the concentrations inducing two or more (C-2) and five or more coughs (C-5) were reached. Results were evaluated in terms of the percentage of subjects whose repeat studies yielded C-2 and C-5 values within one and two doubling concentrations of the initial values. Overall, reproducibility was quite good, with 90-100% of challenges yielding C-2 and C-5 values within two doubling concentrations. Short-term reproducibility Of C-5 was superior to that Of C-2, suggesting that C-5 is the preferred end point for trials involving serial cough challenges performed within a 14-day period. (C) 2003 Elsevier Science Ltd. All rights reserved.